

Freetown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	9	7.8	115.6	(52.8-219.5)	Male	4	5.4	nc	(nc-nc)
Female	1	2.6	nc	(nc-nc)	Female	5	4.4	114.0	(36.8-266.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.8	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
Female	3	1.3	nc	(nc-nc)	Female	2	0.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	7	4.6	150.7	(60.4-310.6)
Female	25	31.9	78.5	(50.8-115.8)	Female	1	3.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	1	1.5	nc	(nc-nc)	Male	3	3.7	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	1.4	nc	(nc-nc)
Male	18	12.2	147.7	(87.5-233.4)	<u>Ovary</u>				
Female	6	9.9	60.8	(22.2-132.4)	Female	5	3.3	150.7	(48.6-351.7)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	2.2	nc	(nc-nc)	Male	2	2.4	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	2	2.1	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.8	nc	(nc-nc)	Male	32	33.3	96.0	(65.7-135.6)
Female	0	0.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	1	2.0	nc	(nc-nc)
Male	6	4.1	146.5	(53.5-318.8)	Female	1	1.0	nc	(nc-nc)
Female	2	2.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	1.4	nc	(nc-nc)
Male	1	1.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.4	nc	(nc-nc)	Male	0	1.4	nc	(nc-nc)
<u>Leukemia</u>					Female	4	4.3	nc	(nc-nc)
Male	2	2.8	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	1.9	nc	(nc-nc)	Female	6	6.8	88.4	(32.3-192.4)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	2.0	nc	(nc-nc)	Male	117	114.0	102.6	(84.9-123.0)
Female	0	0.5	nc	(nc-nc)	Female	86	101.2	85.0	(68.0-105.0)
<u>Lung and Bronchus</u>									
Male	19	15.2	125.3	(75.4-195.7)					
Female	12	13.0	92.3	(47.6-161.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Gardner

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	27	24.6	109.6	(72.2-159.4)	Male	13	14.6	88.8	(47.3-151.9)
Female	8	9.1	87.5	(37.7-172.4)	Female	4	11.0	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	4.6	nc	(nc-nc)	Male	1	3.8	nc	(nc-nc)
Female	1	3.5	nc	(nc-nc)	Female	5	2.8	180.9	(58.3-422.2)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	4	0.7	nc	(nc-nc)	Male	10	13.0	77.1	(36.9-141.8)
Female	81	81.2	99.7	(79.2-123.9)	Female	9	11.5	78.1	(35.6-148.2)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	2	3.4	nc	(nc-nc)	Male	9	8.8	101.9	(46.5-193.4)
<u>Colon / Rectum</u>					Female	4	4.1	nc	(nc-nc)
Male	27	36.0	74.9	(49.4-109.0)	<u>Ovary</u>				
Female	22	35.4	62.2	(39.0-94.1)	Female	6	8.9	67.5	(24.6-146.8)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	6.1	nc	(nc-nc)	Male	11	7.2	153.1	(76.3-274.0)
Female	2	1.8	nc	(nc-nc)	Female	4	7.7	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	2.1	nc	(nc-nc)	Male	76	89.8	84.6	(66.7-105.9)
Female	0	1.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	5	6.1	82.4	(26.6-192.4)
Male	14	10.8	130.0	(71.0-218.1)	Female	1	3.8	nc	(nc-nc)
Female	3	6.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	4	3.6	nc	(nc-nc)
Male	5	3.8	132.5	(42.7-309.3)	<u>Thyroid</u>				
Female	0	1.0	nc	(nc-nc)	Male	3	3.4	nc	(nc-nc)
<u>Leukemia</u>					Female	6	9.1	65.7	(24.0-142.9)
Male	4	8.0	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	6.2	80.3	(25.9-187.3)	Female	21	17.1	122.8	(76.0-187.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	5	5.1	97.3	(31.4-227.1)	Male	289	321.9	89.8	(79.7-100.8)
Female	1	1.8	nc	(nc-nc)	Female	250	293.9	85.1	(74.8-96.3)
<u>Lung and Bronchus</u>									
Male	44	45.6	96.5	(70.1-129.6)					
Female	45	42.1	106.9	(78.0-143.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Georgetown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	6.7	74.8	(24.1-174.4)	Male	5	4.6	108.6	(35.0-253.3)
Female	0	2.4	nc	(nc-nc)	Female	4	3.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.6	nc	(nc-nc)	Male	3	1.1	nc	(nc-nc)
Female	2	1.2	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	5	4.0	126.1	(40.6-294.4)
Female	23	27.7	82.9	(52.5-124.4)	Female	5	3.3	153.4	(49.4-358.0)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	1	1.3	nc	(nc-nc)	Male	6	3.1	195.6	(71.4-425.8)
<u>Colon / Rectum</u>					Female	1	1.3	nc	(nc-nc)
Male	10	10.4	95.9	(45.9-176.3)	<u>Ovary</u>				
Female	9	9.0	99.6	(45.4-189.0)	Female	4	2.9	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	1.9	nc	(nc-nc)	Male	2	2.1	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	0	1.9	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.7	nc	(nc-nc)	Male	31	28.0	110.7	(75.2-157.1)
Female	1	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	1	1.7	nc	(nc-nc)
Male	1	3.5	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
Female	1	2.0	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	3	1.2	nc	(nc-nc)
Male	2	1.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
<u>Leukemia</u>					Female	5	3.7	134.4	(43.3-313.6)
Male	2	2.4	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	1.8	nc	(nc-nc)	Female	6	5.8	103.5	(37.8-225.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	1.7	nc	(nc-nc)	Male	111	97.0	114.5	(94.2-137.8)
Female	0	0.5	nc	(nc-nc)	Female	82	89.7	91.5	(72.7-113.5)
<u>Lung and Bronchus</u>									
Male	19	13.0	146.2	(88.0-228.3)					
Female	12	11.6	103.3	(53.3-180.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Gill

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	1.6	nc	(nc-nc)	Male	2	1.0	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.3	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	6	5.8	103.4	(37.7-225.0)	Female	2	0.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	1	0.3	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.3	nc	(nc-nc)
Male	4	2.4	nc	(nc-nc)	<u>Ovary</u>				
Female	0	2.1	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	5	5.9	84.3	(27.2-196.7)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	0	0.4	nc	(nc-nc)
Male	1	0.7	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.2	nc	(nc-nc)
Male	1	0.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Leukemia</u>					Female	0	0.7	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.4	nc	(nc-nc)	Female	2	1.2	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.4	nc	(nc-nc)	Male	17	21.2	80.2	(46.7-128.4)
Female	0	0.1	nc	(nc-nc)	Female	17	19.2	88.7	(51.6-142.0)
<u>Lung and Bronchus</u>									
Male	1	2.9	nc	(nc-nc)					
Female	4	2.5	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Gloucester

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	37	36.5	101.4	(71.4-139.8)	Male	19	21.8	87.1	(52.4-136.0)
Female	13	14.1	92.0	(48.9-157.3)	Female	20	18.1	110.7	(67.6-170.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	6.8	88.1	(32.2-191.7)	Male	5	5.7	87.1	(28.1-203.2)
Female	6	5.6	106.5	(38.9-231.7)	Female	5	4.3	116.2	(37.5-271.2)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	1.0	nc	(nc-nc)	Male	17	19.2	88.5	(51.5-141.7)
Female	134	136.4	98.2	(82.3-116.3)	Female	19	18.1	105.2	(63.3-164.4)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	6	5.7	104.7	(38.2-227.9)	Male	19	14.0	135.7	(81.7-212.0)
<u>Colon / Rectum</u>					Female	7	6.7	104.6	(41.9-215.6)
Male	47	54.0	87.0	(64.0-115.8)	<u>Ovary</u>				
Female	70	53.9	129.8	(101.2-164.0)	Female	9	14.7	61.3	(28.0-116.3)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	11	9.5	116.1	(57.9-207.8)	Male	15	10.8	138.7	(77.6-228.8)
Female	1	2.8	nc	(nc-nc)	Female	13	11.8	110.3	(58.7-188.7)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	4	2.8	nc	(nc-nc)	Male	131	143.2	91.5	(76.5-108.6)
Female	6	2.1	279.2	(101.9-607.7)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	8	8.9	89.8	(38.7-177.0)
Male	14	16.6	84.2	(46.0-141.2)	Female	8	5.7	140.4	(60.5-276.7)
Female	13	10.6	122.6	(65.2-209.7)	<u>Testis</u>				
<u>Larynx</u>					Male	5	4.6	109.0	(35.1-254.4)
Male	10	5.9	169.0	(80.9-310.8)	<u>Thyroid</u>				
Female	1	1.7	nc	(nc-nc)	Male	5	5.0	99.7	(32.1-232.7)
<u>Leukemia</u>					Female	23	15.4	149.2	(94.5-223.9)
Male	13	11.7	111.5	(59.3-190.6)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	6	9.5	63.0	(23.0-137.1)	Female	28	29.3	95.6	(63.5-138.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	11	8.1	136.6	(68.1-244.5)	Male	506	490.5	103.2	(94.4-112.6)
Female	2	2.9	nc	(nc-nc)	Female	497	473.5	105.0	(95.9-114.6)
<u>Lung and Bronchus</u>									
Male	77	69.3	111.1	(87.7-138.9)					
Female	72	67.1	107.4	(84.0-135.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Goshen

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	1.3	nc	(nc-nc)	Male	2	0.8	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	4	4.8	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.2	nc	(nc-nc)
Male	0	2.0	nc	(nc-nc)	<u>Ovary</u>				
Female	0	1.6	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	0.4	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	6	5.5	108.3	(39.5-235.7)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	0	0.3	nc	(nc-nc)
Male	0	0.6	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.2	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Leukemia</u>					Female	2	0.6	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.3	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.3	nc	(nc-nc)	Male	11	18.6	59.2	(29.5-106.0)
Female	0	0.1	nc	(nc-nc)	Female	8	15.5	51.6	(22.2-101.8)
<u>Lung and Bronchus</u>									
Male	0	2.6	nc	(nc-nc)					
Female	1	2.0	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Gosnold

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.0	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<u>Ovary</u>				
Female	0	0.1	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	0	0.0	nc	(nc-nc)
Male	1	0.1	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.0	nc	(nc-nc)
Male	0	0.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
<u>Leukemia</u>					Female	0	0.0	nc	(nc-nc)
Male	0	0.0	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.0	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.0	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Lung and Bronchus</u>									
Male	0	0.2	nc	(nc-nc)					
Female	0	0.1	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Grafton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	9	14.5	62.0	(28.3-117.8)	Male	12	9.3	128.4	(66.2-224.2)
Female	8	5.4	148.7	(64.0-293.0)	Female	10	8.1	122.9	(58.8-226.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	3.1	nc	(nc-nc)	Male	3	2.3	nc	(nc-nc)
Female	2	2.5	nc	(nc-nc)	Female	1	1.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	3	8.2	nc	(nc-nc)
Female	72	57.7	124.7	(97.6-157.0)	Female	9	7.3	123.3	(56.3-234.0)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	0	2.8	nc	(nc-nc)	Male	4	5.9	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	4	2.7	nc	(nc-nc)
Male	25	21.9	113.9	(73.7-168.2)	<u>Ovary</u>				
Female	24	20.5	117.0	(74.9-174.1)	Female	4	6.2	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	3.8	nc	(nc-nc)	Male	3	4.3	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	Female	3	4.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.4	nc	(nc-nc)	Male	43	57.2	75.2	(54.4-101.2)
Female	1	1.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	1	3.6	nc	(nc-nc)
Male	8	7.0	114.5	(49.3-225.7)	Female	3	2.1	nc	(nc-nc)
Female	5	4.3	115.8	(37.3-270.3)	<u>Testis</u>				
<u>Larynx</u>					Male	2	2.5	nc	(nc-nc)
Male	1	2.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.7	nc	(nc-nc)	Male	5	2.4	212.7	(68.5-496.3)
<u>Leukemia</u>					Female	7	7.7	91.1	(36.5-187.6)
Male	4	5.0	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	3.9	nc	(nc-nc)	Female	10	12.3	81.6	(39.1-150.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	3.4	nc	(nc-nc)	Male	172	201.2	85.5	(73.2-99.3)
Female	2	1.1	nc	(nc-nc)	Female	202	194.5	103.9	(90.0-119.2)
<u>Lung and Bronchus</u>									
Male	31	27.7	111.8	(75.9-158.6)					
Female	23	26.3	87.5	(55.4-131.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Granby

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	7	6.5	107.6	(43.1-221.7)	Male	2	4.1	nc	(nc-nc)
Female	3	2.2	nc	(nc-nc)	Female	4	3.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.3	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.2	nc	(nc-nc)	Male	3	3.6	nc	(nc-nc)
Female	31	24.0	129.2	(87.8-183.4)	Female	1	2.9	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	2	1.1	nc	(nc-nc)	Male	3	2.7	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	1.1	nc	(nc-nc)
Male	8	9.8	81.4	(35.1-160.5)	<u>Ovary</u>				
Female	8	8.2	97.6	(42.0-192.3)	Female	0	2.5	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	1.7	nc	(nc-nc)	Male	2	2.0	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	1.8	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.6	nc	(nc-nc)	Male	22	26.6	82.7	(51.8-125.2)
Female	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	1	1.6	nc	(nc-nc)
Male	4	3.1	nc	(nc-nc)	Female	2	0.8	nc	(nc-nc)
Female	2	1.8	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	1.0	nc	(nc-nc)
Male	1	1.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
<u>Leukemia</u>					Female	1	3.0	nc	(nc-nc)
Male	1	2.2	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	1.5	nc	(nc-nc)	Female	6	5.2	115.2	(42.1-250.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	1.5	nc	(nc-nc)	Male	81	90.6	89.4	(71.0-111.2)
Female	0	0.4	nc	(nc-nc)	Female	72	79.4	90.6	(70.9-114.2)
<u>Lung and Bronchus</u>									
Male	14	12.6	111.5	(60.9-187.0)					
Female	9	10.8	83.0	(37.9-157.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Granville

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	1.5	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.3	nc	(nc-nc)	Male	1	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	5	5.8	85.7	(27.6-200.0)	Female	1	0.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.3	nc	(nc-nc)
Male	1	2.3	nc	(nc-nc)	<u>Ovary</u>				
Female	3	1.9	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	4	6.4	nc	(nc-nc)
Female	1	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	1	0.4	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.2	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Leukemia</u>					Female	0	0.8	nc	(nc-nc)
Male	1	0.5	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	0.4	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.4	nc	(nc-nc)	Male	14	21.7	64.5	(35.2-108.3)
Female	0	0.1	nc	(nc-nc)	Female	16	18.8	85.2	(48.7-138.4)
<u>Lung and Bronchus</u>									
Male	0	3.0	nc	(nc-nc)					
Female	1	2.5	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Great Barrington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	8	9.9	80.5	(34.7-158.6)	Male	7	5.5	126.5	(50.7-260.5)
Female	3	4.1	nc	(nc-nc)	Female	4	4.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.7	nc	(nc-nc)	Male	0	1.5	nc	(nc-nc)
Female	0	1.5	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	5	5.0	100.4	(32.3-234.2)
Female	29	36.1	80.3	(53.8-115.4)	Female	4	5.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	2	1.4	nc	(nc-nc)	Male	4	3.5	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	3	1.8	nc	(nc-nc)
Male	14	14.4	97.1	(53.1-163.0)	<u>Ovary</u>				
Female	16	16.2	98.5	(56.3-160.0)	Female	2	4.0	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	2.4	nc	(nc-nc)	Male	2	2.9	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	3	3.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.7	nc	(nc-nc)	Male	46	35.5	129.5	(94.8-172.7)
Female	0	0.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	3	2.4	nc	(nc-nc)
Male	1	4.2	nc	(nc-nc)	Female	1	1.8	nc	(nc-nc)
Female	3	2.9	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	1.0	nc	(nc-nc)
Male	2	1.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.4	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
<u>Leukemia</u>					Female	1	3.7	nc	(nc-nc)
Male	4	3.1	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	4	2.7	nc	(nc-nc)	Female	5	7.7	65.2	(21.0-152.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	2.0	nc	(nc-nc)	Male	132	126.3	104.5	(87.4-123.9)
Female	1	0.8	nc	(nc-nc)	Female	110	130.9	84.0	(69.1-101.3)
<u>Lung and Bronchus</u>									
Male	20	18.1	110.5	(67.4-170.6)					
Female	19	18.8	101.3	(61.0-158.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Greenfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	18	22.0	81.8	(48.4-129.2)	Male	4	12.5	nc	(nc-nc)
Female	12	9.3	128.5	(66.3-224.4)	Female	8	11.0	73.0	(31.4-143.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	3.8	nc	(nc-nc)	Male	3	3.4	nc	(nc-nc)
Female	2	3.4	nc	(nc-nc)	Female	0	2.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.6	nc	(nc-nc)	Male	7	11.2	62.3	(24.9-128.3)
Female	94	81.5	115.4	(93.2-141.2)	Female	11	11.8	93.2	(46.5-166.7)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	8	3.3	241.2	(103.8-475.2)	Male	10	7.7	130.3	(62.4-239.6)
<u>Colon / Rectum</u>					Female	4	4.2	nc	(nc-nc)
Male	22	32.0	68.8	(43.1-104.2)	<u>Ovary</u>				
Female	36	37.2	96.8	(67.8-134.1)	Female	9	9.0	100.0	(45.6-189.8)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	9	5.4	167.0	(76.2-317.1)	Male	7	6.4	109.7	(43.9-225.9)
Female	2	1.8	nc	(nc-nc)	Female	8	8.0	99.7	(42.9-196.4)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	1.7	nc	(nc-nc)	Male	65	77.4	83.9	(64.8-107.0)
Female	3	1.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	6	5.4	110.6	(40.4-240.6)
Male	7	9.2	75.7	(30.3-156.0)	Female	1	4.1	nc	(nc-nc)
Female	4	6.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	4	2.7	nc	(nc-nc)
Male	3	3.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	1.0	nc	(nc-nc)	Male	3	2.7	nc	(nc-nc)
<u>Leukemia</u>					Female	2	8.8	nc	(nc-nc)
Male	3	7.0	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	6.3	nc	(nc-nc)	Female	11	17.0	64.5	(32.2-115.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	6	4.5	134.1	(49.0-291.9)	Male	244	280.3	87.0	(76.5-98.7)
Female	1	1.9	nc	(nc-nc)	Female	287	297.5	96.5	(85.6-108.3)
<u>Lung and Bronchus</u>									
Male	45	39.9	112.7	(82.2-150.8)					
Female	43	41.9	102.6	(74.2-138.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Groton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	13	7.4	176.3	(93.8-301.5)	Male	5	5.3	93.6	(30.2-218.4)
Female	2	2.5	nc	(nc-nc)	Female	4	4.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	1.9	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	7	4.6	152.3	(61.0-313.9)
Female	44	32.0	137.3	(99.8-184.4)	Female	3	3.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	1	1.6	nc	(nc-nc)	Male	2	3.5	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	1.4	nc	(nc-nc)
Male	14	11.6	120.4	(65.8-202.1)	<u>Ovary</u>				
Female	13	9.6	135.9	(72.3-232.4)	Female	0	3.3	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	2.1	nc	(nc-nc)	Male	1	2.3	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	1	2.0	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.8	nc	(nc-nc)	Male	30	30.3	98.9	(66.7-141.2)
Female	0	0.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	1	1.9	nc	(nc-nc)
Male	7	4.0	176.2	(70.6-363.0)	Female	1	1.0	nc	(nc-nc)
Female	4	2.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	4	1.5	nc	(nc-nc)
Male	0	1.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	0	1.5	nc	(nc-nc)
<u>Leukemia</u>					Female	9	4.6	195.1	(89.0-370.4)
Male	2	2.8	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	2.1	nc	(nc-nc)	Female	10	6.6	152.0	(72.8-279.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	1.9	nc	(nc-nc)	Male	105	108.3	96.9	(79.3-117.3)
Female	1	0.5	nc	(nc-nc)	Female	115	100.6	114.3	(94.4-137.2)
<u>Lung and Bronchus</u>									
Male	5	14.3	35.1	(11.3-81.8)					
Female	8	12.4	64.5	(27.8-127.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Groveland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	8	5.9	136.7	(58.9-269.4)	Male	4	3.8	nc	(nc-nc)
Female	0	2.0	nc	(nc-nc)	Female	4	3.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	1.3	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	Female	2	0.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	1	3.3	nc	(nc-nc)
Female	26	22.8	114.2	(74.6-167.3)	Female	1	2.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	1	1.1	nc	(nc-nc)	Male	1	2.5	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	1.0	nc	(nc-nc)
Male	10	8.9	112.2	(53.7-206.3)	<u>Ovary</u>				
Female	9	7.5	120.4	(55.0-228.6)	Female	3	2.4	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	1.6	nc	(nc-nc)	Male	1	1.8	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	2	1.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.5	nc	(nc-nc)	Male	24	24.1	99.7	(63.8-148.3)
Female	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	2	1.5	nc	(nc-nc)
Male	1	2.9	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
Female	1	1.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.9	nc	(nc-nc)
Male	1	1.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	2	1.0	nc	(nc-nc)
<u>Leukemia</u>					Female	5	3.0	167.3	(53.9-390.3)
Male	1	2.0	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	1.5	nc	(nc-nc)	Female	7	4.8	145.9	(58.4-300.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	1.4	nc	(nc-nc)	Male	88	82.8	106.2	(85.2-130.9)
Female	0	0.4	nc	(nc-nc)	Female	78	74.0	105.4	(83.3-131.6)
<u>Lung and Bronchus</u>									
Male	15	11.4	131.4	(73.5-216.7)					
Female	11	9.8	112.4	(56.0-201.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hadley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	7.3	68.8	(22.2-160.6)	Male	3	3.9	nc	(nc-nc)
Female	2	2.8	nc	(nc-nc)	Female	0	3.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.2	nc	(nc-nc)	Male	3	1.1	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.2	nc	(nc-nc)	Male	3	3.6	nc	(nc-nc)
Female	21	24.0	87.4	(54.1-133.5)	Female	9	3.4	261.9	(119.5-497.1)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	0	0.9	nc	(nc-nc)	Male	3	2.4	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	1.2	nc	(nc-nc)
Male	11	10.4	105.8	(52.7-189.3)	<u>Ovary</u>				
Female	9	10.8	83.1	(37.9-157.8)	Female	3	2.6	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	1.7	nc	(nc-nc)	Male	1	2.1	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	2	2.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.5	nc	(nc-nc)	Male	24	24.9	96.3	(61.7-143.3)
Female	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	2	1.8	nc	(nc-nc)
Male	1	2.9	nc	(nc-nc)	Female	3	1.2	nc	(nc-nc)
Female	2	1.9	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.7	nc	(nc-nc)
Male	0	1.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.3	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
<u>Leukemia</u>					Female	5	2.5	202.4	(65.2-472.4)
Male	1	2.2	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	1.8	nc	(nc-nc)	Female	2	5.1	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	1.4	nc	(nc-nc)	Male	79	90.0	87.7	(69.5-109.4)
Female	1	0.6	nc	(nc-nc)	Female	84	87.1	96.4	(76.9-119.4)
<u>Lung and Bronchus</u>									
Male	7	13.1	53.4	(21.4-110.0)					
Female	10	12.4	80.3	(38.5-147.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Halifax

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	7	8.2	85.3	(34.2-175.7)	Male	4	5.0	nc	(nc-nc)
Female	3	3.0	nc	(nc-nc)	Female	3	4.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.6	nc	(nc-nc)	Male	3	1.3	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	7	4.4	158.4	(63.4-326.3)
Female	27	31.4	86.1	(56.7-125.2)	Female	6	4.0	149.7	(54.7-325.9)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	0	1.4	nc	(nc-nc)	Male	7	3.2	217.5	(87.1-448.2)
<u>Colon / Rectum</u>					Female	0	1.5	nc	(nc-nc)
Male	11	12.2	90.0	(44.8-161.0)	<u>Ovary</u>				
Female	15	11.4	131.4	(73.5-216.8)	Female	5	3.3	149.6	(48.2-349.0)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	2.2	nc	(nc-nc)	Male	1	2.5	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	2	2.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.7	nc	(nc-nc)	Male	25	32.5	76.9	(49.7-113.5)
Female	0	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	3	2.0	nc	(nc-nc)
Male	6	3.8	157.2	(57.4-342.1)	Female	1	1.2	nc	(nc-nc)
Female	8	2.4	334.9	(144.2-659.9)	<u>Testis</u>				
<u>Larynx</u>					Male	1	1.2	nc	(nc-nc)
Male	0	1.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.4	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
<u>Leukemia</u>					Female	1	3.8	nc	(nc-nc)
Male	3	2.7	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	2.1	nc	(nc-nc)	Female	9	6.8	133.0	(60.7-252.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	1.8	nc	(nc-nc)	Male	104	111.8	93.0	(76.0-112.7)
Female	1	0.6	nc	(nc-nc)	Female	123	106.2	115.8	(96.2-138.1)
<u>Lung and Bronchus</u>									
Male	12	15.6	76.9	(39.7-134.3)					
Female	21	14.9	141.0	(87.2-215.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hamilton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	7.9	nc	(nc-nc)	Male	6	5.1	118.6	(43.3-258.2)
Female	2	2.5	nc	(nc-nc)	Female	6	4.0	148.6	(54.3-323.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	1.7	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.2	nc	(nc-nc)	Male	1	4.4	nc	(nc-nc)
Female	25	28.8	86.8	(56.1-128.1)	Female	5	3.4	145.4	(46.9-339.4)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	2	1.4	nc	(nc-nc)	Male	6	3.2	186.6	(68.1-406.2)
<u>Colon / Rectum</u>					Female	0	1.3	nc	(nc-nc)
Male	14	11.9	117.7	(64.3-197.5)	<u>Ovary</u>				
Female	16	9.5	168.6	(96.3-273.8)	Female	2	3.0	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	2.1	nc	(nc-nc)	Male	0	2.4	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	7	2.1	339.3	(135.9-699.2)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.8	nc	(nc-nc)	Male	34	31.0	109.5	(75.8-153.0)
Female	0	0.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	1	2.0	nc	(nc-nc)
Male	1	3.8	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
Female	3	2.1	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	4	1.3	nc	(nc-nc)
Male	0	1.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	2	1.3	nc	(nc-nc)
<u>Leukemia</u>					Female	1	3.9	nc	(nc-nc)
Male	5	2.7	184.2	(59.4-429.8)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	1.9	nc	(nc-nc)	Female	5	6.1	82.4	(26.6-192.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	1.8	nc	(nc-nc)	Male	97	109.1	88.9	(72.1-108.5)
Female	0	0.5	nc	(nc-nc)	Female	93	94.4	98.5	(79.5-120.7)
<u>Lung and Bronchus</u>									
Male	4	15.1	nc	(nc-nc)					
Female	5	12.5	39.9	(12.9-93.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hampden

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	6.0	83.7	(27.0-195.4)	Male	3	3.7	nc	(nc-nc)
Female	2	2.2	nc	(nc-nc)	Female	1	2.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.2	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
Female	2	0.9	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	1	3.2	nc	(nc-nc)
Female	21	22.5	93.5	(57.8-142.9)	Female	2	2.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	2	1.0	nc	(nc-nc)	Male	3	2.5	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	1.1	nc	(nc-nc)
Male	8	9.0	89.1	(38.4-175.6)	<u>Ovary</u>				
Female	13	8.3	156.7	(83.4-268.0)	Female	2	2.4	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	1.6	nc	(nc-nc)	Male	0	1.8	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	2	1.8	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.5	nc	(nc-nc)	Male	18	24.5	73.4	(43.5-116.0)
Female	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	2	1.5	nc	(nc-nc)
Male	4	2.9	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
Female	1	1.7	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.7	nc	(nc-nc)
Male	0	1.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
<u>Leukemia</u>					Female	2	2.6	nc	(nc-nc)
Male	0	2.0	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	1.5	nc	(nc-nc)	Female	4	4.9	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	1.4	nc	(nc-nc)	Male	61	82.7	73.8	(56.4-94.8)
Female	0	0.4	nc	(nc-nc)	Female	73	75.4	96.8	(75.9-121.8)
<u>Lung and Bronchus</u>									
Male	10	11.5	87.1	(41.7-160.2)					
Female	12	10.2	117.4	(60.6-205.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hancock

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	1.1	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	2	3.7	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.2	nc	(nc-nc)
Male	1	1.6	nc	(nc-nc)	<u>Ovary</u>				
Female	1	1.3	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	0.3	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	4.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	0	0.3	nc	(nc-nc)
Male	1	0.5	nc	(nc-nc)	Female	1	0.1	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.1	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Leukemia</u>					Female	0	0.4	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	0.2	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.2	nc	(nc-nc)	Male	7	15.2	46.2	(18.5-95.2)
Female	0	0.1	nc	(nc-nc)	Female	9	12.4	72.8	(33.2-138.1)
<u>Lung and Bronchus</u>									
Male	0	2.1	nc	(nc-nc)					
Female	1	1.7	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hanover

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	10	12.0	83.2	(39.8-153.0)	Male	11	8.1	136.6	(68.1-244.5)
Female	8	4.8	165.7	(71.4-326.6)	Female	8	7.0	113.6	(48.9-223.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	2.7	nc	(nc-nc)	Male	2	2.0	nc	(nc-nc)
Female	3	2.3	nc	(nc-nc)	Female	0	1.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	6	7.0	86.0	(31.4-187.3)
Female	40	52.9	75.6	(54.0-103.0)	Female	6	6.5	92.6	(33.8-201.6)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	2	2.4	nc	(nc-nc)	Male	6	5.4	110.8	(40.5-241.3)
<u>Colon / Rectum</u>					Female	1	2.5	nc	(nc-nc)
Male	24	18.6	129.1	(82.7-192.1)	<u>Ovary</u>				
Female	22	18.3	120.0	(75.2-181.6)	Female	7	5.6	125.2	(50.2-258.1)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	3.4	nc	(nc-nc)	Male	3	3.7	nc	(nc-nc)
Female	3	0.9	nc	(nc-nc)	Female	5	4.0	125.8	(40.6-293.6)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.2	nc	(nc-nc)	Male	52	51.3	101.3	(75.6-132.8)
Female	0	0.9	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	2	3.0	nc	(nc-nc)
Male	3	6.2	nc	(nc-nc)	Female	0	1.9	nc	(nc-nc)
Female	7	3.9	179.0	(71.7-368.8)	<u>Testis</u>				
<u>Larynx</u>					Male	2	2.0	nc	(nc-nc)
Male	3	2.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.6	nc	(nc-nc)	Male	2	2.1	nc	(nc-nc)
<u>Leukemia</u>					Female	9	6.5	138.6	(63.2-263.1)
Male	4	4.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	3.5	nc	(nc-nc)	Female	11	11.4	96.7	(48.2-173.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	3.0	nc	(nc-nc)	Male	165	173.9	94.9	(80.9-110.5)
Female	0	1.0	nc	(nc-nc)	Female	160	174.9	91.5	(77.8-106.8)
<u>Lung and Bronchus</u>									
Male	18	23.5	76.6	(45.4-121.1)					
Female	14	23.7	59.1	(32.3-99.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hanson

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	13	8.2	157.7	(83.9-269.7)	Male	6	5.6	106.3	(38.8-231.4)
Female	3	2.9	nc	(nc-nc)	Female	7	4.7	148.1	(59.3-305.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.9	nc	(nc-nc)	Male	5	1.4	364.2	(117.4-850.0)
Female	4	1.5	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	4	4.9	nc	(nc-nc)
Female	32	34.4	93.0	(63.6-131.3)	Female	3	4.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	1	1.6	nc	(nc-nc)	Male	6	3.8	157.5	(57.5-342.8)
<u>Colon / Rectum</u>					Female	4	1.6	nc	(nc-nc)
Male	23	12.8	179.6	(113.8-269.4)	<u>Ovary</u>				
Female	12	10.8	110.9	(57.2-193.7)	Female	2	3.6	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	2.3	nc	(nc-nc)	Male	0	2.6	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	3	2.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.9	nc	(nc-nc)	Male	28	35.9	78.0	(51.8-112.7)
Female	0	0.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	3	2.1	nc	(nc-nc)
Male	1	4.3	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
Female	2	2.5	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	1.5	nc	(nc-nc)
Male	0	1.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.4	nc	(nc-nc)	Male	2	1.5	nc	(nc-nc)
<u>Leukemia</u>					Female	11	4.6	237.9	(118.6-425.7)
Male	3	3.0	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	2.2	nc	(nc-nc)	Female	10	7.4	134.7	(64.5-247.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	2.1	nc	(nc-nc)	Male	136	121.1	112.3	(94.2-132.8)
Female	2	0.6	nc	(nc-nc)	Female	132	110.6	119.4	(99.9-141.5)
<u>Lung and Bronchus</u>									
Male	20	16.3	122.8	(75.0-189.7)					
Female	27	14.5	186.8	(123.1-271.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hardwick

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	2.8	nc	(nc-nc)	Male	1	1.7	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	Female	2	1.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.6	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	1.5	nc	(nc-nc)
Female	11	10.3	107.3	(53.5-191.9)	Female	1	1.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	1	0.4	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.5	nc	(nc-nc)
Male	5	4.2	118.1	(38.1-275.6)	<u>Ovary</u>				
Female	5	4.0	123.8	(39.9-288.8)	Female	1	1.1	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.7	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.2	nc	(nc-nc)	Male	7	11.0	63.5	(25.4-130.8)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	1	0.7	nc	(nc-nc)
Male	0	1.3	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.4	nc	(nc-nc)
Male	1	0.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	2	0.4	nc	(nc-nc)
<u>Leukemia</u>					Female	0	1.2	nc	(nc-nc)
Male	1	0.9	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	0.7	nc	(nc-nc)	Female	3	2.2	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.6	nc	(nc-nc)	Male	40	38.4	104.1	(74.4-141.8)
Female	0	0.2	nc	(nc-nc)	Female	37	35.7	103.7	(73.0-143.0)
<u>Lung and Bronchus</u>									
Male	10	5.4	185.3	(88.7-340.8)					
Female	1	5.0	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Harvard

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	5.6	89.1	(28.7-207.9)	Male	5	4.2	119.2	(38.4-278.1)
Female	1	1.5	nc	(nc-nc)	Female	1	2.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.4	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	1	3.6	nc	(nc-nc)
Female	19	20.5	92.7	(55.8-144.8)	Female	0	2.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	0	0.9	nc	(nc-nc)	Male	3	2.9	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.9	nc	(nc-nc)
Male	8	9.0	88.5	(38.1-174.4)	<u>Ovary</u>				
Female	5	5.8	85.8	(27.7-200.3)	Female	2	2.1	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	1.7	nc	(nc-nc)	Male	1	1.8	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	0.6	nc	(nc-nc)	Male	27	24.9	108.3	(71.4-157.6)
Female	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	2	1.4	nc	(nc-nc)
Male	4	3.2	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Female	3	1.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	1.2	nc	(nc-nc)
Male	1	1.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
<u>Leukemia</u>					Female	0	2.6	nc	(nc-nc)
Male	3	2.1	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	1.2	433.5	(139.7-1011.6)	Female	7	4.4	157.9	(63.2-325.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	1.6	nc	(nc-nc)	Male	88	85.4	103.0	(82.6-127.0)
Female	1	0.3	nc	(nc-nc)	Female	51	62.5	81.6	(60.7-107.2)
<u>Lung and Bronchus</u>									
Male	10	11.0	90.6	(43.4-166.6)					
Female	5	7.8	63.8	(20.6-148.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Harwich

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	27	26.3	102.7	(67.7-149.5)	Male	21	12.9	163.3	(101.0-249.6)
Female	13	10.1	129.3	(68.8-221.2)	Female	15	9.9	152.0	(85.0-250.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	3.6	nc	(nc-nc)	Male	6	3.8	156.5	(57.1-340.7)
Female	7	3.1	223.0	(89.3-459.4)	Female	2	3.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.7	nc	(nc-nc)	Male	14	11.8	118.3	(64.6-198.5)
Female	81	78.8	102.7	(81.6-127.7)	Female	7	12.0	58.2	(23.3-119.9)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	1	2.7	nc	(nc-nc)	Male	8	7.5	106.3	(45.8-209.5)
<u>Colon / Rectum</u>					Female	6	4.2	143.5	(52.4-312.3)
Male	26	36.5	71.3	(46.6-104.5)	<u>Ovary</u>				
Female	37	38.6	95.8	(67.5-132.1)	Female	5	8.8	56.9	(18.3-132.7)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	9	6.0	149.5	(68.2-283.8)	Male	12	7.4	162.7	(84.0-284.2)
Female	0	2.0	nc	(nc-nc)	Female	12	8.5	140.8	(72.7-246.0)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.2	nc	(nc-nc)	Male	112	88.8	126.1	(103.9-151.8)
Female	1	1.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	5	6.3	79.7	(25.7-185.9)
Male	10	9.8	102.5	(49.1-188.6)	Female	4	4.2	nc	(nc-nc)
Female	5	6.8	73.6	(23.7-171.9)	<u>Testis</u>				
<u>Larynx</u>					Male	5	1.5	331.3	(106.8-773.2)
Male	2	3.6	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	1.0	nc	(nc-nc)	Male	3	2.2	nc	(nc-nc)
<u>Leukemia</u>					Female	5	6.8	73.7	(23.8-172.0)
Male	4	7.4	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	6	6.2	96.5	(35.3-210.1)	Female	21	17.0	123.6	(76.5-188.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	4.6	nc	(nc-nc)	Male	332	313.1	106.0	(94.9-118.1)
Female	1	2.0	nc	(nc-nc)	Female	284	298.1	95.3	(84.5-107.0)
<u>Lung and Bronchus</u>									
Male	32	47.3	67.6	(46.2-95.5)					
Female	42	45.9	91.5	(66.0-123.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hatfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	4.5	nc	(nc-nc)	Male	4	2.6	nc	(nc-nc)
Female	0	1.6	nc	(nc-nc)	Female	1	2.0	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.8	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	2	0.6	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	3	2.3	nc	(nc-nc)
Female	21	15.7	133.7	(82.7-204.4)	Female	2	2.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	0	0.6	nc	(nc-nc)	Male	5	1.8	285.2	(91.9-665.4)
<u>Colon / Rectum</u>					Female	1	0.8	nc	(nc-nc)
Male	3	6.7	nc	(nc-nc)	<u>Ovary</u>				
Female	4	6.2	nc	(nc-nc)	Female	1	1.7	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	1.2	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	3	1.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	0.3	nc	(nc-nc)	Male	17	17.8	95.6	(55.7-153.2)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	1	1.1	nc	(nc-nc)
Male	2	2.1	nc	(nc-nc)	Female	2	0.6	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.5	nc	(nc-nc)
Male	1	0.7	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<u>Leukemia</u>					Female	2	1.7	nc	(nc-nc)
Male	0	1.4	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	1.1	nc	(nc-nc)	Female	3	3.4	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	1.0	nc	(nc-nc)	Male	59	60.6	97.4	(74.1-125.6)
Female	0	0.3	nc	(nc-nc)	Female	54	54.2	99.6	(74.8-129.9)
<u>Lung and Bronchus</u>									
Male	7	8.6	81.2	(32.5-167.3)					
Female	7	7.8	90.2	(36.1-185.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Haverhill

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	44	56.7	77.7	(56.4-104.3)	Male	22	34.8	63.2	(39.6-95.7)
Female	20	23.6	84.7	(51.7-130.8)	Female	21	31.7	66.3	(41.0-101.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	9	11.4	78.8	(35.9-149.5)	Male	6	8.9	67.5	(24.7-147.0)
Female	5	10.1	49.7	(16.0-115.9)	Female	6	7.2	83.6	(30.5-181.9)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.6	nc	(nc-nc)	Male	24	30.8	78.0	(50.0-116.1)
Female	197	226.0	87.2	(75.4-100.2)	Female	34	30.8	110.5	(76.5-154.4)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	7	10.3	68.1	(27.3-140.3)	Male	16	21.2	75.4	(43.0-122.4)
<u>Colon / Rectum</u>					Female	8	11.2	71.6	(30.8-141.1)
Male	88	83.7	105.2	(84.4-129.6)	<u>Ovary</u>				
Female	98	91.8	106.7	(86.6-130.1)	Female	27	24.5	110.2	(72.6-160.3)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	17	14.4	118.4	(69.0-189.6)	Male	17	16.7	102.0	(59.4-163.3)
Female	9	4.6	194.8	(88.9-369.8)	Female	18	19.9	90.5	(53.6-143.1)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	5	5.3	95.1	(30.6-221.9)	Male	179	209.5	85.4	(73.4-98.9)
Female	5	4.4	114.6	(36.9-267.5)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	13	14.0	92.6	(49.2-158.3)
Male	33	25.5	129.2	(89.0-181.5)	Female	6	9.9	60.7	(22.2-132.1)
Female	14	17.6	79.4	(43.3-133.2)	<u>Testis</u>				
<u>Larynx</u>					Male	11	9.4	117.5	(58.6-210.3)
Male	8	8.9	90.2	(38.8-177.8)	<u>Thyroid</u>				
Female	3	2.7	nc	(nc-nc)	Male	6	8.4	71.8	(26.2-156.3)
<u>Leukemia</u>					Female	22	28.1	78.3	(49.1-118.6)
Male	17	19.3	88.3	(51.4-141.4)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	14	16.9	82.8	(45.2-139.0)	Female	63	47.4	132.8	(102.1-170.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	12	12.2	98.4	(50.8-171.9)	Male	702	754.0	93.1	(86.3-100.3)
Female	3	4.8	nc	(nc-nc)	Female	742	797.0	93.1	(86.5-100.0)
<u>Lung and Bronchus</u>									
Male	117	105.0	111.4	(92.2-133.6)					
Female	102	109.8	92.9	(75.7-112.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hawley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	0.6	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	1.5	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.1	nc	(nc-nc)
Male	1	0.8	nc	(nc-nc)	<u>Ovary</u>				
Female	0	0.5	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.0	nc	(nc-nc)	Male	3	2.3	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	0	0.1	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	1	0.1	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.0	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<u>Leukemia</u>					Female	0	0.2	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.1	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.1	nc	(nc-nc)	Male	6	7.7	78.4	(28.6-170.6)
Female	0	0.0	nc	(nc-nc)	Female	2	4.9	nc	(nc-nc)
<u>Lung and Bronchus</u>									
Male	0	1.1	nc	(nc-nc)					
Female	0	0.7	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Heath

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	0.9	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	1	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	3	3.0	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.1	nc	(nc-nc)
Male	0	1.3	nc	(nc-nc)	<u>Ovary</u>				
Female	0	0.9	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.2	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	3	3.8	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	1	0.2	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.1	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<u>Leukemia</u>					Female	0	0.4	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.2	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.2	nc	(nc-nc)	Male	10	12.6	79.4	(38.0-146.0)
Female	0	0.1	nc	(nc-nc)	Female	6	9.5	63.4	(23.2-138.0)
<u>Lung and Bronchus</u>									
Male	1	1.7	nc	(nc-nc)					
Female	0	1.2	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hingham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	13	23.4	55.5	(29.5-94.9)	Male	28	14.2	197.7	(131.3-285.7)
Female	12	9.3	128.7	(66.4-224.8)	Female	23	12.1	190.6	(120.8-286.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	4.5	nc	(nc-nc)	Male	4	3.7	nc	(nc-nc)
Female	5	3.9	129.6	(41.8-302.4)	Female	3	2.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.7	nc	(nc-nc)	Male	19	12.5	152.5	(91.7-238.1)
Female	102	93.5	109.1	(88.9-132.4)	Female	15	12.0	124.9	(69.8-206.0)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	3	3.9	nc	(nc-nc)	Male	6	9.4	63.7	(23.3-138.7)
<u>Colon / Rectum</u>					Female	4	4.5	nc	(nc-nc)
Male	37	35.1	105.5	(74.3-145.4)	<u>Ovary</u>				
Female	28	35.7	78.4	(52.1-113.4)	Female	4	10.0	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	8	6.2	128.0	(55.1-252.3)	Male	4	7.1	nc	(nc-nc)
Female	2	1.8	nc	(nc-nc)	Female	6	7.8	77.3	(28.2-168.3)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.7	nc	(nc-nc)	Male	89	95.2	93.5	(75.1-115.0)
Female	1	1.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	2	5.7	nc	(nc-nc)
Male	7	11.1	63.3	(25.4-130.5)	Female	1	3.8	nc	(nc-nc)
Female	11	7.1	153.9	(76.7-275.4)	<u>Testis</u>				
<u>Larynx</u>					Male	6	2.7	223.3	(81.5-486.1)
Male	1	3.9	nc	(nc-nc)	<u>Thyroid</u>				
Female	2	1.1	nc	(nc-nc)	Male	4	3.3	nc	(nc-nc)
<u>Leukemia</u>					Female	13	10.3	125.9	(66.9-215.2)
Male	10	7.6	131.0	(62.7-241.0)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	6.4	nc	(nc-nc)	Female	17	20.3	83.7	(48.7-134.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	5.3	nc	(nc-nc)	Male	287	321.0	89.4	(79.4-100.4)
Female	1	1.9	nc	(nc-nc)	Female	313	318.7	98.2	(87.6-109.7)
<u>Lung and Bronchus</u>									
Male	24	45.0	53.3	(34.2-79.4)					
Female	35	44.5	78.7	(54.8-109.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hinsdale

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	1.9	nc	(nc-nc)	Male	6	1.2	495.4	(180.9-1078.3)
Female	2	0.6	nc	(nc-nc)	Female	3	0.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.4	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	7	6.8	102.6	(41.1-211.4)	Female	3	0.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	2	0.8	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.3	nc	(nc-nc)
Male	3	2.9	nc	(nc-nc)	<u>Ovary</u>				
Female	6	2.3	259.6	(94.8-565.1)	Female	2	0.7	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	0.5	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.2	nc	(nc-nc)	Male	10	8.1	123.6	(59.2-227.4)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	0	0.5	nc	(nc-nc)
Male	2	0.9	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.3	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Leukemia</u>					Female	1	0.9	nc	(nc-nc)
Male	0	0.6	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.4	nc	(nc-nc)	Female	3	1.5	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.5	nc	(nc-nc)	Male	34	27.0	126.2	(87.4-176.3)
Female	0	0.1	nc	(nc-nc)	Female	33	22.5	146.6	(100.9-205.9)
<u>Lung and Bronchus</u>									
Male	2	3.7	nc	(nc-nc)					
Female	3	3.1	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Holbrook

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	11	13.1	83.7	(41.7-149.8)	Male	6	7.6	78.5	(28.7-170.9)
Female	6	4.8	124.8	(45.6-271.5)	Female	2	6.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	2.4	nc	(nc-nc)	Male	4	2.0	nc	(nc-nc)
Female	4	1.9	nc	(nc-nc)	Female	1	1.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	4	6.8	nc	(nc-nc)
Female	48	46.3	103.7	(76.5-137.6)	Female	4	6.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	3	2.0	nc	(nc-nc)	Male	7	4.8	146.9	(58.8-302.7)
<u>Colon / Rectum</u>					Female	4	2.3	nc	(nc-nc)
Male	8	19.2	41.7	(17.9-82.1)	<u>Ovary</u>				
Female	13	17.8	73.2	(38.9-125.2)	Female	4	5.0	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	3.3	149.7	(48.2-349.3)	Male	2	3.8	nc	(nc-nc)
Female	2	0.9	nc	(nc-nc)	Female	4	3.9	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	4	1.0	nc	(nc-nc)	Male	30	50.9	58.9	(39.7-84.1)
Female	0	0.8	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	5	3.2	157.2	(50.7-367.0)
Male	3	5.8	nc	(nc-nc)	Female	5	1.8	273.2	(88.0-637.5)
Female	2	3.7	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	1.6	nc	(nc-nc)
Male	4	2.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.6	nc	(nc-nc)	Male	4	1.7	nc	(nc-nc)
<u>Leukemia</u>					Female	4	5.3	nc	(nc-nc)
Male	3	4.2	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	3.2	157.0	(50.6-366.3)	Female	11	10.1	109.3	(54.5-195.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	5	2.8	179.4	(57.8-418.7)	Male	144	174.4	82.6	(69.6-97.2)
Female	1	1.0	nc	(nc-nc)	Female	163	160.7	101.4	(86.4-118.2)
<u>Lung and Bronchus</u>									
Male	28	25.1	111.7	(74.2-161.5)					
Female	31	23.5	131.7	(89.5-186.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Holden

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	16	18.8	85.0	(48.5-138.0)	Male	9	11.4	79.2	(36.1-150.3)
Female	5	6.8	73.7	(23.7-171.9)	Female	8	9.1	88.2	(38.0-173.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	3.6	nc	(nc-nc)	Male	5	3.0	167.3	(53.9-390.4)
Female	2	2.9	nc	(nc-nc)	Female	2	2.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.5	nc	(nc-nc)	Male	10	10.0	99.6	(47.7-183.2)
Female	74	68.9	107.5	(84.4-134.9)	Female	7	8.9	78.8	(31.6-162.4)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	0	2.9	nc	(nc-nc)	Male	6	7.4	80.6	(29.4-175.4)
<u>Colon / Rectum</u>					Female	2	3.3	nc	(nc-nc)
Male	17	28.1	60.5	(35.2-96.9)	<u>Ovary</u>				
Female	24	26.2	91.7	(58.7-136.4)	Female	8	7.4	108.7	(46.8-214.2)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	4.9	nc	(nc-nc)	Male	7	5.6	124.5	(49.9-256.5)
Female	0	1.3	nc	(nc-nc)	Female	2	5.7	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.4	nc	(nc-nc)	Male	64	73.8	86.8	(66.8-110.8)
Female	0	1.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	3	4.6	nc	(nc-nc)
Male	2	8.7	nc	(nc-nc)	Female	1	2.8	nc	(nc-nc)
Female	4	5.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	2.2	nc	(nc-nc)
Male	3	3.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.8	nc	(nc-nc)	Male	5	2.6	191.6	(61.7-447.2)
<u>Leukemia</u>					Female	8	7.9	101.0	(43.5-198.9)
Male	7	6.1	114.1	(45.7-235.0)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	4	4.7	nc	(nc-nc)	Female	11	14.7	74.9	(37.4-134.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	4.2	nc	(nc-nc)	Male	205	254.2	80.6	(70.0-92.5)
Female	0	1.4	nc	(nc-nc)	Female	206	234.5	87.9	(76.3-100.7)
<u>Lung and Bronchus</u>									
Male	26	35.6	73.1	(47.7-107.1)					
Female	21	32.4	64.8	(40.1-99.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Holland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	2.2	nc	(nc-nc)	Male	0	1.5	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.5	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	1.3	nc	(nc-nc)
Female	2	7.8	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	0	0.4	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	0.4	nc	(nc-nc)
Male	9	3.4	264.7	(120.8-502.6)	<u>Ovary</u>				
Female	4	2.3	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.6	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	9	9.1	99.4	(45.4-188.7)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	0	0.5	nc	(nc-nc)
Male	1	1.1	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.4	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<u>Leukemia</u>					Female	0	1.1	nc	(nc-nc)
Male	2	0.8	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.5	nc	(nc-nc)	Female	3	1.6	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.6	nc	(nc-nc)	Male	31	31.5	98.3	(66.8-139.5)
Female	0	0.1	nc	(nc-nc)	Female	21	24.7	85.0	(52.6-130.0)
<u>Lung and Bronchus</u>									
Male	3	4.2	nc	(nc-nc)					
Female	5	3.1	160.6	(51.7-374.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Holliston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	14	11.8	118.4	(64.7-198.7)	Male	9	8.2	110.3	(50.3-209.4)
Female	5	4.1	120.7	(38.9-281.7)	Female	8	6.8	117.1	(50.4-230.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	2.8	nc	(nc-nc)	Male	5	2.0	251.9	(81.2-587.9)
Female	1	2.2	nc	(nc-nc)	Female	2	1.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	6	7.0	85.4	(31.2-185.9)
Female	52	51.0	102.1	(76.2-133.8)	Female	5	5.7	87.5	(28.2-204.2)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	6	2.4	249.8	(91.2-543.7)	Male	9	5.6	161.7	(73.8-307.0)
<u>Colon / Rectum</u>					Female	0	2.3	nc	(nc-nc)
Male	22	18.5	119.0	(74.5-180.1)	<u>Ovary</u>				
Female	12	15.5	77.4	(40.0-135.2)	Female	7	5.3	132.8	(53.2-273.6)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	3.4	147.6	(47.6-344.4)	Male	7	3.7	190.4	(76.3-392.2)
Female	1	0.8	nc	(nc-nc)	Female	9	3.4	268.6	(122.6-510.0)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.2	nc	(nc-nc)	Male	71	51.7	137.2	(107.2-173.1)
Female	1	0.8	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	2	2.9	nc	(nc-nc)
Male	8	6.3	127.2	(54.8-250.6)	Female	4	1.6	nc	(nc-nc)
Female	5	3.6	140.0	(45.1-326.7)	<u>Testis</u>				
<u>Larynx</u>					Male	3	2.0	nc	(nc-nc)
Male	1	2.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.6	nc	(nc-nc)	Male	3	2.1	nc	(nc-nc)
<u>Leukemia</u>					Female	4	6.7	nc	(nc-nc)
Male	3	4.2	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	3.1	nc	(nc-nc)	Female	10	10.9	91.7	(43.9-168.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	3.1	nc	(nc-nc)	Male	211	174.4	121.0	(105.2-138.5)
Female	2	0.9	nc	(nc-nc)	Female	154	160.9	95.7	(81.2-112.0)
<u>Lung and Bronchus</u>									
Male	25	23.4	106.9	(69.1-157.8)					
Female	12	20.9	57.4	(29.6-100.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Holyoke

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	36	43.2	83.3	(58.4-115.4)	Male	18	24.4	73.9	(43.8-116.8)
Female	17	17.8	95.3	(55.5-152.5)	Female	23	21.7	106.1	(67.2-159.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	7.9	nc	(nc-nc)	Male	5	6.6	76.0	(24.5-177.3)
Female	9	7.1	126.5	(57.7-240.1)	Female	4	5.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.2	nc	(nc-nc)	Male	13	22.0	59.1	(31.4-101.0)
Female	135	156.9	86.0	(72.1-101.8)	Female	22	22.6	97.2	(60.9-147.2)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	7	6.7	105.0	(42.1-216.4)	Male	17	14.7	116.0	(67.5-185.7)
<u>Colon / Rectum</u>					Female	7	8.1	86.9	(34.8-179.0)
Male	57	62.3	91.5	(69.3-118.5)	<u>Ovary</u>				
Female	76	70.1	108.4	(85.4-135.7)	Female	14	17.3	80.8	(44.1-135.5)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	14	10.5	133.3	(72.8-223.7)	Male	12	12.5	96.2	(49.6-168.0)
Female	2	3.5	nc	(nc-nc)	Female	13	15.2	85.5	(45.5-146.3)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	3.5	nc	(nc-nc)	Male	150	153.3	97.8	(82.8-114.8)
Female	1	3.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	8	10.6	75.6	(32.6-149.0)
Male	10	18.1	55.3	(26.5-101.8)	Female	6	7.7	78.1	(28.5-170.1)
Female	16	12.7	125.8	(71.9-204.3)	<u>Testis</u>				
<u>Larynx</u>					Male	5	5.6	89.9	(29.0-209.8)
Male	7	6.4	109.0	(43.7-224.5)	<u>Thyroid</u>				
Female	2	1.9	nc	(nc-nc)	Male	3	5.3	nc	(nc-nc)
<u>Leukemia</u>					Female	14	18.0	77.8	(42.5-130.5)
Male	11	14.1	77.9	(38.9-139.5)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	12	12.6	95.4	(49.2-166.7)	Female	49	33.1	148.1	(109.6-195.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	9	8.6	104.4	(47.6-198.2)	Male	493	551.6	89.4	(81.7-97.6)
Female	1	3.6	nc	(nc-nc)	Female	557	573.7	97.1	(89.2-105.5)
<u>Lung and Bronchus</u>									
Male	74	78.9	93.8	(73.6-117.7)					
Female	87	80.7	107.9	(86.4-133.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hopedale

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	9	7.0	128.6	(58.7-244.2)	Male	5	4.1	122.1	(39.4-285.0)
Female	0	2.7	nc	(nc-nc)	Female	2	3.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.3	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	3	1.1	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.2	nc	(nc-nc)	Male	1	3.6	nc	(nc-nc)
Female	22	25.7	85.6	(53.6-129.6)	Female	2	3.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	1	1.1	nc	(nc-nc)	Male	2	2.5	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	1.3	nc	(nc-nc)
Male	5	10.2	49.0	(15.8-114.4)	<u>Ovary</u>				
Female	10	10.6	94.7	(45.3-174.1)	Female	2	2.8	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	1.7	nc	(nc-nc)	Male	2	2.0	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	2	2.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.5	nc	(nc-nc)	Male	20	24.7	81.0	(49.5-125.1)
Female	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	0	1.7	nc	(nc-nc)
Male	4	3.0	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
Female	3	2.0	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.9	nc	(nc-nc)
Male	0	1.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
<u>Leukemia</u>					Female	2	3.0	nc	(nc-nc)
Male	2	2.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	1.9	nc	(nc-nc)	Female	3	5.3	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	1.5	nc	(nc-nc)	Male	74	89.9	82.3	(64.6-103.3)
Female	0	0.6	nc	(nc-nc)	Female	71	90.3	78.6	(61.4-99.2)
<u>Lung and Bronchus</u>									
Male	11	12.8	85.9	(42.8-153.8)					
Female	6	12.5	47.8	(17.5-104.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hopkinton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	9	9.2	97.6	(44.5-185.3)	Male	5	7.0	71.5	(23.0-166.8)
Female	1	3.4	nc	(nc-nc)	Female	6	6.2	97.1	(35.5-211.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	2.5	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
Female	2	2.0	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	8	6.0	134.2	(57.8-264.5)
Female	42	43.0	97.6	(70.4-132.0)	Female	5	4.9	102.7	(33.1-239.7)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	1	2.3	nc	(nc-nc)	Male	3	4.6	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	3	1.9	nc	(nc-nc)
Male	8	14.8	54.1	(23.3-106.6)	<u>Ovary</u>				
Female	13	13.3	97.8	(52.0-167.2)	Female	7	4.4	158.6	(63.5-326.8)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	2.7	nc	(nc-nc)	Male	8	2.9	277.0	(119.3-545.8)
Female	1	0.7	nc	(nc-nc)	Female	4	2.8	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	1.1	nc	(nc-nc)	Male	41	38.3	107.1	(76.8-145.2)
Female	0	0.8	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	1	2.4	nc	(nc-nc)
Male	2	5.2	nc	(nc-nc)	Female	0	1.4	nc	(nc-nc)
Female	0	3.0	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	3	2.1	nc	(nc-nc)
Male	4	1.7	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.5	nc	(nc-nc)	Male	2	2.0	nc	(nc-nc)
<u>Leukemia</u>					Female	7	6.3	110.4	(44.2-227.4)
Male	5	3.7	136.8	(44.1-319.2)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	2.9	nc	(nc-nc)	Female	4	8.6	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	2.5	nc	(nc-nc)	Male	130	138.3	94.0	(78.5-111.6)
Female	0	0.7	nc	(nc-nc)	Female	118	136.5	86.5	(71.6-103.5)
<u>Lung and Bronchus</u>									
Male	13	17.9	72.6	(38.6-124.2)					
Female	13	16.6	78.3	(41.6-133.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hubbardston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	8	2.9	279.8	(120.5-551.3)	Male	1	2.2	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	Female	3	1.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	0.8	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.1	nc	(nc-nc)	Male	0	1.9	nc	(nc-nc)
Female	15	12.4	121.2	(67.8-199.9)	Female	2	1.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	0	0.7	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.5	nc	(nc-nc)
Male	5	4.6	108.8	(35.1-254.0)	<u>Ovary</u>				
Female	3	3.6	nc	(nc-nc)	Female	0	1.3	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	0.8	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	2	0.8	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.4	nc	(nc-nc)	Male	20	12.5	160.1	(97.8-247.3)
Female	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	1	0.7	nc	(nc-nc)
Male	2	1.6	nc	(nc-nc)	Female	2	0.4	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.7	nc	(nc-nc)
Male	1	0.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<u>Leukemia</u>					Female	2	1.9	nc	(nc-nc)
Male	2	1.1	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.8	nc	(nc-nc)	Female	1	2.5	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.8	nc	(nc-nc)	Male	55	43.7	125.7	(94.7-163.7)
Female	0	0.2	nc	(nc-nc)	Female	44	38.8	113.5	(82.5-152.4)
<u>Lung and Bronchus</u>									
Male	6	5.7	105.4	(38.5-229.4)					
Female	5	4.7	107.1	(34.5-249.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hudson

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	18	18.3	98.5	(58.4-155.7)	Male	7	11.7	59.7	(23.9-123.0)
Female	11	6.9	158.7	(79.1-284.0)	Female	11	9.8	112.7	(56.2-201.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	3.8	156.9	(57.3-341.6)	Male	0	2.9	nc	(nc-nc)
Female	2	3.1	nc	(nc-nc)	Female	3	2.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.5	nc	(nc-nc)	Male	8	10.2	78.5	(33.8-154.7)
Female	62	71.8	86.3	(66.2-110.7)	Female	9	9.1	98.4	(44.9-186.9)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	5	3.2	154.0	(49.6-359.4)	Male	5	7.6	66.2	(21.3-154.5)
<u>Colon / Rectum</u>					Female	4	3.4	nc	(nc-nc)
Male	28	27.6	101.3	(67.3-146.4)	<u>Ovary</u>				
Female	30	25.9	115.6	(78.0-165.1)	Female	8	7.6	104.7	(45.1-206.2)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	4.9	nc	(nc-nc)	Male	7	5.5	126.8	(50.8-261.3)
Female	0	1.4	nc	(nc-nc)	Female	7	5.7	123.3	(49.4-254.0)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.7	nc	(nc-nc)	Male	65	74.7	87.0	(67.2-110.9)
Female	0	1.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	2	4.5	nc	(nc-nc)
Male	9	8.9	101.0	(46.1-191.7)	Female	5	2.7	187.0	(60.3-436.4)
Female	4	5.5	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	4	3.0	nc	(nc-nc)
Male	1	3.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	2	0.9	nc	(nc-nc)	Male	3	2.9	nc	(nc-nc)
<u>Leukemia</u>					Female	4	8.9	nc	(nc-nc)
Male	10	6.2	161.5	(77.3-297.0)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	4.8	103.7	(33.4-241.9)	Female	10	15.5	64.5	(30.9-118.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	4.3	nc	(nc-nc)	Male	236	255.8	92.3	(80.9-104.8)
Female	0	1.4	nc	(nc-nc)	Female	237	243.3	97.4	(85.4-110.6)
<u>Lung and Bronchus</u>									
Male	48	35.3	135.9	(100.2-180.2)					
Female	35	34.1	102.7	(71.5-142.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Hull

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	22	12.1	181.3	(113.6-274.5)	Male	13	7.7	168.6	(89.7-288.3)
Female	7	4.2	165.2	(66.2-340.4)	Female	11	6.4	172.7	(86.1-309.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	2.4	nc	(nc-nc)	Male	1	2.0	nc	(nc-nc)
Female	3	1.9	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.4	nc	(nc-nc)	Male	7	6.7	104.7	(41.9-215.8)
Female	52	48.0	108.3	(80.9-142.0)	Female	6	5.7	105.1	(38.4-228.7)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	1	2.2	nc	(nc-nc)	Male	7	5.1	137.8	(55.2-284.0)
<u>Colon / Rectum</u>					Female	1	2.2	nc	(nc-nc)
Male	21	18.4	113.9	(70.5-174.2)	<u>Ovary</u>				
Female	20	15.8	126.7	(77.4-195.7)	Female	10	5.0	198.4	(95.0-364.9)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	7	3.3	213.3	(85.4-439.4)	Male	1	3.7	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	3	3.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	1.0	nc	(nc-nc)	Male	58	50.5	114.9	(87.3-148.6)
Female	2	0.8	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	4	3.0	nc	(nc-nc)
Male	7	5.9	117.7	(47.2-242.5)	Female	3	1.6	nc	(nc-nc)
Female	7	3.5	200.6	(80.4-413.3)	<u>Testis</u>				
<u>Larynx</u>					Male	2	1.7	nc	(nc-nc)
Male	6	2.1	287.0	(104.8-624.8)	<u>Thyroid</u>				
Female	3	0.6	nc	(nc-nc)	Male	2	1.9	nc	(nc-nc)
<u>Leukemia</u>					Female	7	5.9	117.8	(47.2-242.7)
Male	8	4.0	200.1	(86.2-394.3)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	2.9	170.8	(55.0-398.6)	Female	12	10.5	114.2	(59.0-199.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	2.9	nc	(nc-nc)	Male	217	170.2	127.5	(111.1-145.7)
Female	0	0.9	nc	(nc-nc)	Female	206	156.2	131.9	(114.5-151.2)
<u>Lung and Bronchus</u>									
Male	26	23.6	110.4	(72.1-161.7)					
Female	36	21.3	168.8	(118.2-233.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Huntington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	6	2.1	292.7	(106.9-637.0)	Male	2	1.4	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	Female	2	1.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.5	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	4	1.2	nc	(nc-nc)
Female	9	7.8	115.3	(52.6-218.8)	Female	1	1.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	1	0.4	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.4	nc	(nc-nc)
Male	3	3.2	nc	(nc-nc)	<u>Ovary</u>				
Female	0	2.7	nc	(nc-nc)	Female	2	0.8	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	0.6	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	5	8.7	57.5	(18.5-134.1)
Female	1	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	1	0.5	nc	(nc-nc)
Male	1	1.0	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.3	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
<u>Leukemia</u>					Female	0	1.0	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	0.5	nc	(nc-nc)	Female	2	1.7	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.5	nc	(nc-nc)	Male	31	29.6	104.8	(71.2-148.7)
Female	0	0.1	nc	(nc-nc)	Female	28	25.8	108.6	(72.2-157.0)
<u>Lung and Bronchus</u>									
Male	4	3.9	nc	(nc-nc)					
Female	4	3.4	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Ipswich

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	18	15.6	115.1	(68.2-181.9)	Male	10	9.5	105.8	(50.6-194.5)
Female	5	6.4	77.6	(25.0-181.1)	Female	9	8.1	110.7	(50.5-210.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	3.0	nc	(nc-nc)	Male	1	2.5	nc	(nc-nc)
Female	1	2.5	nc	(nc-nc)	Female	5	2.0	253.7	(81.8-592.0)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.5	nc	(nc-nc)	Male	9	8.3	108.3	(49.4-205.6)
Female	64	62.5	102.4	(78.8-130.7)	Female	8	8.3	96.9	(41.7-190.9)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	1	2.6	nc	(nc-nc)	Male	7	6.2	113.0	(45.3-232.7)
<u>Colon / Rectum</u>					Female	4	3.0	nc	(nc-nc)
Male	17	23.4	72.7	(42.3-116.4)	<u>Ovary</u>				
Female	33	24.9	132.5	(91.2-186.1)	Female	6	6.7	89.3	(32.6-194.3)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	4.1	nc	(nc-nc)	Male	3	4.7	nc	(nc-nc)
Female	0	1.3	nc	(nc-nc)	Female	5	5.4	92.5	(29.8-215.9)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.2	nc	(nc-nc)	Male	79	61.9	127.6	(101.0-159.0)
Female	0	0.9	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	3	3.8	nc	(nc-nc)
Male	13	7.3	177.8	(94.6-304.1)	Female	3	2.6	nc	(nc-nc)
Female	2	4.8	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	6	1.9	321.5	(117.4-699.9)
Male	2	2.6	nc	(nc-nc)	<u>Thyroid</u>				
Female	2	0.7	nc	(nc-nc)	Male	3	2.2	nc	(nc-nc)
<u>Leukemia</u>					Female	6	6.8	87.6	(32.0-190.7)
Male	4	5.0	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	6	4.3	138.4	(50.5-301.2)	Female	18	13.4	134.4	(79.6-212.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	3.5	nc	(nc-nc)	Male	221	212.1	104.2	(90.9-118.9)
Female	1	1.3	nc	(nc-nc)	Female	233	216.2	107.8	(94.4-122.5)
<u>Lung and Bronchus</u>									
Male	27	29.9	90.4	(59.6-131.6)					
Female	35	30.3	115.4	(80.3-160.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Kingston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	12	13.3	90.5	(46.7-158.1)	Male	12	7.9	151.9	(78.4-265.4)
Female	14	5.0	278.4	(152.1-467.1)	Female	7	6.7	105.2	(42.1-216.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	2.5	nc	(nc-nc)	Male	4	2.1	nc	(nc-nc)
Female	3	2.1	nc	(nc-nc)	Female	1	1.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	9	7.0	128.3	(58.5-243.6)
Female	43	48.6	88.4	(64.0-119.1)	Female	7	6.5	107.5	(43.1-221.5)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	1	2.2	nc	(nc-nc)	Male	6	4.9	122.6	(44.8-266.8)
<u>Colon / Rectum</u>					Female	3	2.4	nc	(nc-nc)
Male	20	19.5	102.5	(62.6-158.3)	<u>Ovary</u>				
Female	16	19.6	81.8	(46.7-132.8)	Female	8	5.2	152.9	(65.8-301.3)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	3.3	nc	(nc-nc)	Male	6	3.9	154.3	(56.4-335.9)
Female	0	1.0	nc	(nc-nc)	Female	8	4.2	189.3	(81.5-373.0)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.1	nc	(nc-nc)	Male	47	48.9	96.1	(70.6-127.8)
Female	0	0.8	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	4	3.3	nc	(nc-nc)
Male	8	5.9	135.7	(58.4-267.3)	Female	1	2.1	nc	(nc-nc)
Female	6	3.8	159.4	(58.2-346.9)	<u>Testis</u>				
<u>Larynx</u>					Male	2	1.8	nc	(nc-nc)
Male	1	2.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.6	nc	(nc-nc)	Male	1	1.8	nc	(nc-nc)
<u>Leukemia</u>					Female	4	5.8	nc	(nc-nc)
Male	4	4.4	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	3.6	nc	(nc-nc)	Female	10	10.2	98.3	(47.1-180.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	2.8	nc	(nc-nc)	Male	193	174.4	110.7	(95.6-127.5)
Female	0	1.0	nc	(nc-nc)	Female	175	169.8	103.1	(88.4-119.5)
<u>Lung and Bronchus</u>									
Male	32	24.6	130.0	(88.9-183.5)					
Female	23	23.3	98.6	(62.5-147.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Lakeville

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	10	10.0	100.4	(48.0-184.6)	Male	7	6.4	108.7	(43.6-224.0)
Female	5	3.8	130.3	(42.0-304.1)	Female	4	5.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	2.1	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
Female	3	1.7	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	4	5.6	nc	(nc-nc)
Female	29	39.8	72.9	(48.8-104.7)	Female	3	5.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	1	1.8	nc	(nc-nc)	Male	6	4.2	143.6	(52.4-312.6)
<u>Colon / Rectum</u>					Female	1	1.9	nc	(nc-nc)
Male	15	15.1	99.3	(55.5-163.8)	<u>Ovary</u>				
Female	14	14.9	93.9	(51.3-157.6)	Female	0	4.2	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	2.7	nc	(nc-nc)	Male	1	3.0	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	1	3.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.9	nc	(nc-nc)	Male	39	40.1	97.2	(69.1-132.9)
Female	0	0.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	1	2.5	nc	(nc-nc)
Male	5	4.9	102.7	(33.1-239.8)	Female	1	1.6	nc	(nc-nc)
Female	1	3.0	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	6	1.6	384.0	(140.2-835.8)
Male	3	1.7	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.5	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
<u>Leukemia</u>					Female	4	5.0	nc	(nc-nc)
Male	3	3.4	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	2.8	nc	(nc-nc)	Female	9	8.3	108.1	(49.3-205.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	2.3	nc	(nc-nc)	Male	132	139.0	95.0	(79.5-112.6)
Female	0	0.8	nc	(nc-nc)	Female	106	134.8	78.6	(64.4-95.1)
<u>Lung and Bronchus</u>									
Male	17	19.0	89.4	(52.0-143.1)					
Female	18	18.0	100.1	(59.3-158.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Lancaster

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	5.5	90.3	(29.1-210.6)	Male	6	4.1	147.4	(53.8-320.8)
Female	3	2.0	nc	(nc-nc)	Female	3	2.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	1.4	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	Female	2	0.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.2	nc	(nc-nc)	Male	3	3.5	nc	(nc-nc)
Female	27	20.5	131.4	(86.6-191.2)	Female	0	2.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	2	1.0	nc	(nc-nc)	Male	3	2.5	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	1.0	nc	(nc-nc)
Male	9	8.7	103.8	(47.4-197.2)	<u>Ovary</u>				
Female	9	7.8	115.4	(52.7-219.1)	Female	2	2.2	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	1.5	nc	(nc-nc)	Male	2	1.7	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	1	1.7	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.8	nc	(nc-nc)	Male	25	22.7	110.4	(71.4-162.9)
Female	1	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	1	1.4	nc	(nc-nc)
Male	1	2.9	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
Female	2	1.5	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	1.5	nc	(nc-nc)
Male	1	1.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
<u>Leukemia</u>					Female	5	2.7	187.0	(60.2-436.3)
Male	2	2.1	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	1.5	nc	(nc-nc)	Female	9	4.3	208.3	(95.0-395.4)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	1.4	nc	(nc-nc)	Male	86	81.4	105.7	(84.5-130.5)
Female	0	0.4	nc	(nc-nc)	Female	85	70.4	120.7	(96.4-149.3)
<u>Lung and Bronchus</u>									
Male	11	10.6	103.6	(51.6-185.4)					
Female	10	9.4	106.6	(51.0-196.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Lanesborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	7	3.5	198.8	(79.6-409.6)	Male	8	2.2	370.9	(159.7-730.9)
Female	1	1.1	nc	(nc-nc)	Female	0	1.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.7	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.1	nc	(nc-nc)	Male	0	1.9	nc	(nc-nc)
Female	23	11.9	193.5	(122.6-290.3)	Female	5	1.5	340.0	(109.6-793.5)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	3	0.5	nc	(nc-nc)	Male	3	1.4	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.6	nc	(nc-nc)
Male	6	5.3	113.7	(41.5-247.4)	<u>Ovary</u>				
Female	4	4.2	nc	(nc-nc)	Female	2	1.3	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.9	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.3	nc	(nc-nc)	Male	14	14.2	98.5	(53.8-165.3)
Female	1	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	1	0.9	nc	(nc-nc)
Male	1	1.7	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.4	nc	(nc-nc)
Male	1	0.6	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<u>Leukemia</u>					Female	2	1.5	nc	(nc-nc)
Male	1	1.1	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.8	nc	(nc-nc)	Female	5	2.5	196.2	(63.2-457.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	0.8	nc	(nc-nc)	Male	61	48.3	126.3	(96.6-162.2)
Female	1	0.2	nc	(nc-nc)	Female	58	39.5	146.8	(111.5-189.8)
<u>Lung and Bronchus</u>									
Male	6	6.8	88.6	(32.4-192.9)					
Female	6	5.4	110.4	(40.3-240.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Lawrence

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	47	53.1	88.4	(65.0-117.6)	Male	15	34.9	43.0	(24.0-70.9)
Female	18	22.0	81.6	(48.4-129.0)	Female	11	33.4	32.9	(16.4-58.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	16	12.7	125.8	(71.8-204.3)	Male	7	8.5	82.6	(33.1-170.2)
Female	10	11.2	88.9	(42.6-163.6)	Female	6	6.7	89.8	(32.8-195.4)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.5	nc	(nc-nc)	Male	20	30.8	64.8	(39.6-100.1)
Female	167	223.8	74.6	(63.7-86.9)	Female	36	29.9	120.6	(84.4-166.9)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	19	11.2	170.1	(102.4-265.7)	Male	27	21.0	128.8	(84.8-187.3)
<u>Colon / Rectum</u>					Female	4	11.0	nc	(nc-nc)
Male	79	79.7	99.2	(78.5-123.6)	<u>Ovary</u>				
Female	75	85.6	87.6	(68.9-109.8)	Female	15	24.3	61.7	(34.5-101.8)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	10	13.7	72.9	(34.9-134.2)	Male	22	15.8	139.5	(87.4-211.3)
Female	6	4.3	139.8	(51.1-304.3)	Female	22	18.5	119.2	(74.7-180.5)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	6	6.6	90.3	(33.0-196.5)	Male	206	199.7	103.2	(89.6-118.3)
Female	6	5.6	107.5	(39.2-233.9)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	14	13.3	105.0	(57.4-176.2)
Male	13	25.1	51.8	(27.6-88.6)	Female	4	9.2	nc	(nc-nc)
Female	10	17.2	58.1	(27.8-106.9)	<u>Testis</u>				
<u>Larynx</u>					Male	3	12.2	nc	(nc-nc)
Male	10	8.5	117.7	(56.3-216.4)	<u>Thyroid</u>				
Female	4	2.6	nc	(nc-nc)	Male	6	9.1	65.8	(24.0-143.2)
<u>Leukemia</u>					Female	20	31.8	62.8	(38.4-97.0)
Male	16	20.4	78.6	(44.9-127.7)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	17	17.6	96.5	(56.2-154.5)	Female	50	46.6	107.3	(79.6-141.4)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	11	12.0	91.8	(45.8-164.2)	Male	691	733.5	94.2	(87.3-101.5)
Female	4	4.6	nc	(nc-nc)	Female	637	782.2	81.4	(75.2-88.0)
<u>Lung and Bronchus</u>									
Male	114	99.1	115.1	(94.9-138.2)					
Female	83	103.4	80.3	(63.9-99.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Lee

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	7.6	65.5	(21.1-152.7)	Male	7	4.4	158.8	(63.6-327.1)
Female	3	2.8	nc	(nc-nc)	Female	6	3.5	172.3	(62.9-375.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.4	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	4	3.9	nc	(nc-nc)
Female	22	26.5	83.1	(52.1-125.9)	Female	4	3.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	1	1.1	nc	(nc-nc)	Male	1	2.8	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	3	1.3	nc	(nc-nc)
Male	13	11.2	116.1	(61.8-198.6)	<u>Ovary</u>				
Female	22	10.5	208.5	(130.6-315.7)	Female	1	2.9	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	1.9	nc	(nc-nc)	Male	2	2.2	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	1	2.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	0.6	nc	(nc-nc)	Male	25	29.5	84.9	(54.9-125.3)
Female	1	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	2	1.9	nc	(nc-nc)
Male	5	3.4	147.7	(47.6-344.6)	Female	0	1.1	nc	(nc-nc)
Female	0	2.1	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.9	nc	(nc-nc)
Male	1	1.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
<u>Leukemia</u>					Female	4	2.9	nc	(nc-nc)
Male	2	2.4	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	1.8	nc	(nc-nc)	Female	8	5.7	139.8	(60.2-275.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	1.6	nc	(nc-nc)	Male	97	101.0	96.0	(77.9-117.2)
Female	1	0.6	nc	(nc-nc)	Female	105	92.5	113.5	(92.9-137.4)
<u>Lung and Bronchus</u>									
Male	15	14.5	103.6	(57.9-170.9)					
Female	19	13.4	142.1	(85.5-222.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Leicester

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	13	10.5	124.2	(66.1-212.4)	Male	2	6.6	nc	(nc-nc)
Female	3	3.9	nc	(nc-nc)	Female	3	5.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	2.2	nc	(nc-nc)	Male	4	1.7	nc	(nc-nc)
Female	2	1.7	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.3	nc	(nc-nc)	Male	3	5.8	nc	(nc-nc)
Female	39	39.8	98.1	(69.7-134.1)	Female	5	5.2	96.5	(31.1-225.3)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	2	1.8	nc	(nc-nc)	Male	3	4.2	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	1.9	nc	(nc-nc)
Male	13	15.6	83.1	(44.2-142.2)	<u>Ovary</u>				
Female	17	15.1	112.6	(65.5-180.2)	Female	3	4.3	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	2.7	nc	(nc-nc)	Male	4	3.1	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	4	3.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.0	nc	(nc-nc)	Male	30	40.3	74.4	(50.2-106.3)
Female	0	0.8	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	1	2.6	nc	(nc-nc)
Male	5	4.9	102.7	(33.1-239.6)	Female	1	1.6	nc	(nc-nc)
Female	0	3.0	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	6	1.6	364.6	(133.1-793.6)
Male	2	1.7	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.5	nc	(nc-nc)	Male	0	1.6	nc	(nc-nc)
<u>Leukemia</u>					Female	2	5.0	nc	(nc-nc)
Male	4	3.6	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	2.8	nc	(nc-nc)	Female	8	8.4	95.1	(40.9-187.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	2.4	nc	(nc-nc)	Male	121	142.2	85.1	(70.6-101.6)
Female	0	0.8	nc	(nc-nc)	Female	126	136.7	92.2	(76.8-109.7)
<u>Lung and Bronchus</u>									
Male	19	19.7	96.6	(58.1-150.9)					
Female	27	18.8	143.9	(94.8-209.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Lenox

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	12	8.6	139.1	(71.8-242.9)	Male	8	4.5	177.1	(76.3-349.0)
Female	1	3.6	nc	(nc-nc)	Female	8	3.7	213.6	(92.0-421.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	1.3	nc	(nc-nc)	Male	2	1.3	nc	(nc-nc)
Female	3	1.2	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	5	4.1	121.9	(39.3-284.5)
Female	28	29.5	94.8	(63.0-137.0)	Female	6	4.4	135.6	(49.5-295.1)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	0	1.1	nc	(nc-nc)	Male	2	2.7	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	1.5	nc	(nc-nc)
Male	12	12.3	97.9	(50.5-171.1)	<u>Ovary</u>				
Female	18	14.4	124.7	(73.9-197.1)	Female	3	3.3	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	2.0	nc	(nc-nc)	Male	5	2.5	202.5	(65.3-472.6)
Female	1	0.7	nc	(nc-nc)	Female	3	3.1	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.5	nc	(nc-nc)	Male	19	30.0	63.4	(38.1-99.0)
Female	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	2	2.1	nc	(nc-nc)
Male	5	3.4	148.1	(47.7-345.5)	Female	0	1.6	nc	(nc-nc)
Female	2	2.5	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.6	nc	(nc-nc)
Male	1	1.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.4	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
<u>Leukemia</u>					Female	1	2.7	nc	(nc-nc)
Male	2	2.5	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	2.3	nc	(nc-nc)	Female	5	6.3	79.5	(25.6-185.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	1.6	nc	(nc-nc)	Male	97	105.9	91.6	(74.3-111.8)
Female	0	0.7	nc	(nc-nc)	Female	100	110.2	90.8	(73.9-110.4)
<u>Lung and Bronchus</u>									
Male	9	15.4	58.4	(26.7-110.9)					
Female	10	16.0	62.6	(30.0-115.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Leominster

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2001-2005

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	37	41.4	89.4	(63.0-123.3)	Male	16	25.4	62.9	(35.9-102.2)
Female	15	16.5	90.7	(50.7-149.6)	Female	9	22.4	40.2	(18.3-76.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	10	8.3	120.2	(57.5-221.1)	Male	5	6.5	76.7	(24.7-179.0)
Female	7	7.1	99.0	(39.6-203.9)	Female	4	5.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.2	nc	(nc-nc)	Male	26	22.4	116.0	(75.7-170.0)
Female	142	161.0	88.2	(74.3-104.0)	Female	20	21.6	92.7	(56.6-143.2)
<u>Cervix Uteri</u>					<u>Oral Cavity and Pharynx</u>				
Female	7	7.3	96.0	(38.5-197.9)	Male	7	15.8	44.2	(17.7-91.2)
<u>Colon / Rectum</u>					Female	9	7.9	114.0	(52.0-216.4)
Male	70	61.4	114.0	(88.9-144.1)	<u>Ovary</u>				
Female	59	63.5	92.9	(70.7-119.8)	Female	22	17.4	126.7	(79.4-191.8)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	15	10.7	140.7	(78.7-232.0)	Male	18	12.2	147.1	(87.1-232.5)
Female	3	3.2	nc	(nc-nc)	Female	14	13.8	101.3	(55.3-170.0)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	7	3.7	187.2	(75.0-385.8)	Male	148	159.0	93.1	(78.7-109.4)
Female	3	3.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney and Renal Pelvis</u>					Male	13	10.2	127.5	(67.8-218.0)
Male	17	19.0	89.3	(52.0-143.1)	Female	14	6.8	207.1	(113.1-347.5)
Female	10	12.5	80.0	(38.3-147.1)	<u>Testis</u>				
<u>Larynx</u>					Male	12	6.6	183.1	(94.5-319.9)
Male	8	6.6	120.5	(51.9-237.4)	<u>Thyroid</u>				
Female	3	1.9	nc	(nc-nc)	Male	3	6.1	nc	(nc-nc)
<u>Leukemia</u>					Female	12	19.9	60.2	(31.0-105.1)
Male	15	13.9	107.9	(60.4-178.0)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	9	11.7	77.0	(35.2-146.2)	Female	26	34.0	76.5	(49.9-112.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	12	9.1	132.2	(68.3-231.0)	Male	574	558.6	102.8	(94.5-111.5)
Female	3	3.4	nc	(nc-nc)	Female	496	562.2	88.2	(80.6-96.3)
<u>Lung and Bronchus</u>									
Male	85	78.2	108.6	(86.8-134.3)					
Female	68	78.1	87.0	(67.6-110.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;